This HTML5 document contains 156 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/bindingdb/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/kegg-drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/drugbank/
n30http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n24http://www.rxlist.com/cgi/generic/
n21http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n29http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/chebi/
n3http://linked.opendata.cz/ontology/drugbank/
n15http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n16http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/atc/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01026/identifier/pdb/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01026
rdf:type
n3:Drug
n3:description
Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. [PubChem]
n3:dosage
n12:271B55C2-363D-11E5-9242-09173F13E4C5 n12:271B55C3-363D-11E5-9242-09173F13E4C5 n12:271B55C4-363D-11E5-9242-09173F13E4C5 n12:271B55C5-363D-11E5-9242-09173F13E4C5 n12:271B55C6-363D-11E5-9242-09173F13E4C5 n12:271B55C7-363D-11E5-9242-09173F13E4C5 n12:271B55C8-363D-11E5-9242-09173F13E4C5 n12:271B55C9-363D-11E5-9242-09173F13E4C5 n12:271B55CA-363D-11E5-9242-09173F13E4C5 n12:271B55CB-363D-11E5-9242-09173F13E4C5 n12:271B55CC-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Goeders NE, Peltier RL, Guerin GF: Ketoconazole reduces low dose cocaine self-administration in rats. Drug Alcohol Depend. 1998 Dec 1;53(1):67-77. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10933341 # Berwaerts J, Verhelst J, Mahler C, Abs R: Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol. 1999 Jun;13(3):175-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10451809 # Kazy Z, Puho E, Czeizel AE: Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit Anom (Kyoto). 2005 Mar;45(1):5-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15737124 # Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE: A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002 Nov-Dec;15(6):434-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12476017
n3:group
investigational approved
n3:halfLife
2 hours
n3:indication
For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
owl:sameAs
n20:DB01026 n30:DB01026
dcterms:title
Ketoconazole
adms:identifier
n18:Ketoconazole n22:KTN n23:PA450146 n25:D00351 n26:0145-0003-05 n27:DB01026 n28:31768 n29:48339
n3:mechanismOfAction
Ketoconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Other mechanisms may involve the inhibition of endogenous respiration, interaction with membrane phospholipids, inhibition of yeast transformation to mycelial forms, inhibition of purine uptake, and impairment of triglyceride and/or phospholipid biosynthesis. Ketoconazole can also inhibit the synthesis of thromboxane and sterols such as aldosterone, cortisol, and testosterone.
n3:packager
n4:271B55A1-363D-11E5-9242-09173F13E4C5 n4:271B55A2-363D-11E5-9242-09173F13E4C5 n4:271B5580-363D-11E5-9242-09173F13E4C5 n4:271B55A9-363D-11E5-9242-09173F13E4C5 n4:271B55A0-363D-11E5-9242-09173F13E4C5 n4:271B55AA-363D-11E5-9242-09173F13E4C5 n4:271B55A7-363D-11E5-9242-09173F13E4C5 n4:271B55A8-363D-11E5-9242-09173F13E4C5 n4:271B55AD-363D-11E5-9242-09173F13E4C5 n4:271B55AB-363D-11E5-9242-09173F13E4C5 n4:271B5581-363D-11E5-9242-09173F13E4C5 n4:271B55AC-363D-11E5-9242-09173F13E4C5 n4:271B557E-363D-11E5-9242-09173F13E4C5 n4:271B557F-363D-11E5-9242-09173F13E4C5 n4:271B558C-363D-11E5-9242-09173F13E4C5 n4:271B558D-363D-11E5-9242-09173F13E4C5 n4:271B558A-363D-11E5-9242-09173F13E4C5 n4:271B558B-363D-11E5-9242-09173F13E4C5 n4:271B5590-363D-11E5-9242-09173F13E4C5 n4:271B5591-363D-11E5-9242-09173F13E4C5 n4:271B558E-363D-11E5-9242-09173F13E4C5 n4:271B558F-363D-11E5-9242-09173F13E4C5 n4:271B5584-363D-11E5-9242-09173F13E4C5 n4:271B5585-363D-11E5-9242-09173F13E4C5 n4:271B5582-363D-11E5-9242-09173F13E4C5 n4:271B5583-363D-11E5-9242-09173F13E4C5 n4:271B5588-363D-11E5-9242-09173F13E4C5 n4:271B5589-363D-11E5-9242-09173F13E4C5 n4:271B5586-363D-11E5-9242-09173F13E4C5 n4:271B5587-363D-11E5-9242-09173F13E4C5 n4:271B559F-363D-11E5-9242-09173F13E4C5 n4:271B559E-363D-11E5-9242-09173F13E4C5 n4:271B559C-363D-11E5-9242-09173F13E4C5 n4:271B559D-363D-11E5-9242-09173F13E4C5 n4:271B559A-363D-11E5-9242-09173F13E4C5 n4:271B559B-363D-11E5-9242-09173F13E4C5 n4:271B5594-363D-11E5-9242-09173F13E4C5 n4:271B5595-363D-11E5-9242-09173F13E4C5 n4:271B5592-363D-11E5-9242-09173F13E4C5 n4:271B5593-363D-11E5-9242-09173F13E4C5 n4:271B55A5-363D-11E5-9242-09173F13E4C5 n4:271B5598-363D-11E5-9242-09173F13E4C5 n4:271B55A6-363D-11E5-9242-09173F13E4C5 n4:271B5599-363D-11E5-9242-09173F13E4C5 n4:271B55A3-363D-11E5-9242-09173F13E4C5 n4:271B5596-363D-11E5-9242-09173F13E4C5 n4:271B55A4-363D-11E5-9242-09173F13E4C5 n4:271B5597-363D-11E5-9242-09173F13E4C5
n3:patent
n21:7179475 n21:5456851
n3:synonym
Nizoral Extina Nizoral a-D Xolegel Ketoconazole Ketozole Ketoconazolum SID456469 Ketoconazol
n3:toxicity
Hepatotoxicity, LD<sub>50</sub>=86 mg/kg (orally in rat)
n8:hasAHFSCode
n9:84-04-08-08 n9:08-14-08
n3:foodInteraction
Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication. Take with food. Avoid alcohol.
n3:proteinBinding
99% (in vitro, plasma protein binding)
n3:synthesisReference
U.S. Patent 4,144,346.
n10:hasConcept
n11:M0011987
foaf:page
n15:ketoconazole.html n16:niz1297.shtml n24:ketocon.htm
n3:IUPAC-Name
n6:271B55D1-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B55D7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B55D6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B55D3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B55D4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B55D5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B55CF-363D-11E5-9242-09173F13E4C5 n6:271B55E6-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B55E8-363D-11E5-9242-09173F13E4C5 n6:271B55CD-363D-11E5-9242-09173F13E4C5 n6:271B55D0-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B55CE-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n13:D01AC08 n13:J02AB02 n13:G01AF11
n3:H-Bond-Acceptor-Count
n6:271B55DD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B55DE-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B55D8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B55D9-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B55DB-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B55DA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B55DC-363D-11E5-9242-09173F13E4C5
n3:absorption
Moderate
n3:affectedOrganism
Fungi
n3:casRegistryNumber
65277-42-1
n3:category
n3:containedIn
n7:271B55BB-363D-11E5-9242-09173F13E4C5 n7:271B55BC-363D-11E5-9242-09173F13E4C5 n7:271B55B9-363D-11E5-9242-09173F13E4C5 n7:271B55BA-363D-11E5-9242-09173F13E4C5 n7:271B55BF-363D-11E5-9242-09173F13E4C5 n7:271B55C0-363D-11E5-9242-09173F13E4C5 n7:271B55BD-363D-11E5-9242-09173F13E4C5 n7:271B55BE-363D-11E5-9242-09173F13E4C5 n7:271B55B3-363D-11E5-9242-09173F13E4C5 n7:271B55B4-363D-11E5-9242-09173F13E4C5 n7:271B55B1-363D-11E5-9242-09173F13E4C5 n7:271B55B2-363D-11E5-9242-09173F13E4C5 n7:271B55B7-363D-11E5-9242-09173F13E4C5 n7:271B55B8-363D-11E5-9242-09173F13E4C5 n7:271B55B5-363D-11E5-9242-09173F13E4C5 n7:271B55B6-363D-11E5-9242-09173F13E4C5 n7:271B55C1-363D-11E5-9242-09173F13E4C5 n7:271B55AF-363D-11E5-9242-09173F13E4C5 n7:271B55B0-363D-11E5-9242-09173F13E4C5 n7:271B55AE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B55E2-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B55E4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B55E5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B55E7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B55E1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B55E0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B55E3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B55D2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B55DF-363D-11E5-9242-09173F13E4C5